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Abstract
Drug targeting to the colon via the oral administration route for local treatment of e.g. inflam-
matory bowel disease and colonic cancer has several advantages such as needle-free
administration and low infection risk. A new source for delivery is plant-polysaccharide
based delivery platforms such as Rhamnogalacturonan-I (RG-I). In the gastro-intestinal
tract the RG-I is only degraded by the action of the colonic microflora. For assessment of
potential drug delivery properties, RG-I based microcapsules (~1 μm in diameter) were pre-
pared by an interfacial poly-addition reaction. The cross-linked capsules were loaded with a
fluorescent dye (model drug). The capsules showed negligible and very little in vitro release
when subjected to media simulating gastric and intestinal fluids, respectively. However,
upon exposure to a cocktail of commercial RG-I cleaving enzymes, ~ 9 times higher release
was observed, demonstrating that the capsules can be opened by enzymatic degradation.
The combined results suggest a potential platform for targeted drug delivery in the terminal
gastro-intestinal tract.
Introduction
The uptake of drugs via the oral route is an attractive choice for drug administration as it is
easy and convenient. To enhance the therapeutic effect of such oral approaches, several site-
specific drug delivery systems, e.g. targeting the colon, have been developed, for example based
on pH change, gastro-intestinal (GIT) transit times or bacterial degradation. To formulate
drug delivery systems with tailored drug releasing properties, the development of new poly-
mers with unique physicochemical properties is a prerequisite. In general, polysaccharides are
interesting as oral based drug carriers, because they are non-toxic and exhibit good biocom-
patibility and controlled release properties [1]. In particular, pectin is considered an important
polysaccharide in this context [2], as it is only degraded by enzymes from the human colonic
microflora. Therefore, its suitability for efficient colon drug delivery has been investigated
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previously. However, the focus in the past has primarily been on solid particles/beads [1, 3]
and to a lesser extent on hydrogel particles [4, 5] or oil-core microcapsules [6]. Microcapsules
based on rhamnogalacturonan-I (RG-I), which is the focus in the present paper, have not pre-
viously been reported.
RG-I belongs to the class of pectic polysaccharides. The pectin macromolecule comprises
four major polysaccharides: Rhamnogalaturonan I, Rhamnogalaturonan II, xylogalacturonan
and homogalacturonan, of which homogalacturonan (HG) is the most abundant. HG consists
of long linear segments of partially methyl-esterified (1–4)-linked α-D- galacturonic acid. It is
used as an ingredient (E440) in food industry and often simply referred to as pectin. Drug
release from beads of HG has previously been studied [1, 3] and the inherent self-assembly
properties of HG, mediated by divalent cations (e.g. zinc and calcium), have made it an attrac-
tive material for drug delivery purposes. However, the drug release from beads prepared in
this way is time-dependent and due to gradual dissolution/erosion of the beads. In particular,
calcium pectinate beads have been shown to disintegrate before reaching the colon [7, 8]. To
prevent this, beads can be coated with a silica layer to reduce swelling and delay drug release
[7, 8].
RG-I is the second most abundant polysaccharide of the pectin family. It was recently
shown that RG-I by itself reduces the proliferation of certain types of colon cancer cells, dem-
onstrating its potential as a bioactive compound [9]. In addition, RG-I has beneficial effects on
the fecal microflora [10, 11].
The present study aims to develop a proof-of-concept comprising the preparation of RG-I-
polyurea/urethane capsules with aqueous cores and to evaluate their potential use as a platform
for encapsulation and delivery of drugs to the colon via oral administration. As RG-I can be
degraded by the actions of enzymes in the human colon only [10, 11], RG-I based capsules
would be expected to have colon-targeted delivery properties. In that case, the RG-I would act
as enzymatically degradable “patches/sites” on the capsule wall surface, allowing for efficient
release of the capsule content into the colon. This is the first report of using RG-I to generate
microcapsules with aqueous cores.
Materials and Methods
Materials
2,4-Toluene diisocyanate (TDI), sodium dodecyl sulfate (SDS), sulforhodamine 101 (SR101),
cyclohexane, gelatin from bovine skin (type B), 4-bromophenylboronic acid (BPBA), NaCl,
tris(hydroxymethyl)aminomethane (Tris), maleic acid, bile extract porcine, pepsin from por-
cine gastric mucosa, pancreatin from porcine pancreas and calcium chloride dihydrate were
purchased from Sigma Aldrich. Gastric lipase from rabbit (RGL) was a gift from Dr. Fre´de´ric
Carrie´re (Laboratory of Enzymology at Interfaces and Physiology of Lipolysis, Centre National
de la recherche´ scientifique, Marseille, France) and phospholipid from egg was received from
Lipoid (Ludwigshafen, Germany). GRINSTED1 PGPR 90 Kosher (poly(glycerol)poly(rici-
noleate)) was a kind gift from Danisco, Denmark. Pectinex Smash XXL (declared enzyme: Pec-
tin lyase), Novozyme 863 (Polygalacturonase), Viscozyme L (Beta-glucanase (endo-1,3(4)-),
multi-component plant cell wall degrading enzyme preparation) and Pulpzyme HC (Xylanase
(endo-1,4-)) were kind gifts from Novozymes A/S, Denmark.
Enzymatic extraction of RG-I
The RG-I was enzymatically extracted from potato pulp, that is the waste product after starch
production. The procedure and characterization are described in detail by Byg et al [12].
Briefly, the pectin macromolecule used in this study contains long linear segments of
RG-I Microcapsules for Targeted Drug Release
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alternating highly acetylated and partially methyl-esterified α-D- galacturonic acid and L-
rhamnose (rhamnogalacturonan I–RG-I) essentially devoid of linear α-D- galacturonic acid
(homogalacturonan—HG). Potato RG-I is documented to have a high degree of acetylation
(DA) and is found to be in the range of DA 54.7 [13]. The RG-I, produced by the procedure
described in Byg et al. [12] was further treated with PG-III (CAE 46195, exo-polygalacturo-
nase, Novozymes, Denmark) until the galacturonic acid:rhamnose (GalA:Rha) ratio was 1.08.
A GalA:Rha ratio of 1 is a RG-I molecule devoid of the homogalacturonan tail [12]. The alter-
nating GalA-Rha backbone carries branches of L-arabinans and D-galactans, the former highly
branched and the latter predominantly linear, see Fig 1A [14]. In mol% the resulting sugar pro-
file was fucose 2.2; rhamnose 6.7; arabinose 10.5; galactose (Gal) 73.2; glucose 0.0; xylose 0.1;
mannose 0.0; galacturonic acid 7.3.
Microcapsule synthesis
150 mg of RG-I and 21 mg of NaCl was dissolved in 1.31g Milli-Q water. For release experi-
ments, 1 mg of the fluorescent dye sulforhodamine 101 was also added to the aqueous phase.
This dye was chosen due to previously reported suitable characteristics, such as pH- and tem-
perature-insensitivity, no reaction with 2,4-Toluene diisocyanate (TDI) [15, 16] and also
because the fluorescence signal is comparable in the different simulated media, see S1 Fig. An
amount of 7.5 g of a cyclohexane solution, containing 80 mg of poly(glycerol)poly(ricinoleate)
(PGPR), was added and the phases were mixed (magnetic stirring) vigorously for 1–1.5 h. The
PGPR was used as a surfactant to stabilize the water droplets in cyclohexane. The crude emul-
sion was subsequently subjected to ultra-sonication (120s, 80% amplitude, pulse 20s, pause
10s, Sonics Sonifier, 750W, 1/2” tip) under ice-cooling. Afterwards, 3 g of cyclohexane, con-
taining 1.4× 10−3 mol (0.2 mL) or 1.3×10−3 mol (0.19 mL) of TDI was added drop wise. The
polyaddition reaction proceeded overnight at 25˚C under slow magnetic stirring (400 rpm).
A third capsules sample was also prepared for FTIR using a lower amount of cross-linker,
0.44×10−3 mol (0.06 mL). However, due to lack of RG-I, the amount of chemicals used in the
synthesis of the third capsule type was scaled down; 63 mg RG-I, 8.6 mg NaCl, 0.55 g Milli-Q
Fig 1. Rhamnogalacturonan-I. (a) The chemical structure of Rhamnogalacturonan-I (b) Molar mass distribution of
Rhamnogalacturonan-I.
doi:10.1371/journal.pone.0168050.g001
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water, 3.1 g of cyclohexane solution containing 33 mg of PGPR and then 1.3 g of cyclohexane
containing 0.18×10−3 mol (0.025 mL) TDI.
A 0.5 wt% capsule suspension in Milli-Q water was prepared by mixing the retrieved sus-
pension of capsules in cyclohexane with an 8 mM SDS solution in MilliQ water. The suspen-
sion was sonicated at low amplitude 30% for 20s (Sonics Sonifier, 750W, 1/2” tip) to obtain a
good dispersion. A low amplitude was used in order to not break the capsules. The solution
was left overnight at RT and under magnetic stirring, to evaporate the cyclohexane; in the
morning the water content was adjusted in order to account for any water evaporation. A
freshly prepared 0.5 wt% capsules suspension in Milli-Q water was used in the release experi-
ments. For FTIR and 13C CP/MAS NMR measurements, dry capsule samples were obtained
by freezing the suspension of capsules in cyclohexane, followed by freeze-drying.
The encapsulation efficiency was analyzed from the amount of free dye (= not encapsu-
lated) present in the 0.5 wt% capsule suspension in Milli-Q water. Samples were centrifuged at
4000 rpm for 5 min, the supernatant was collected and the amount of free dye was analyzed
with fluorescence spectroscopy. The reported value is an average of three measurements.
In vitro release studies
Gastric step. 20 mL of concentrated fasted state simulated gastric fluid, SGF (pH ~ 1.64),
was added to a thermostated glass vessel (37˚C) with overhead stirring and a lid and the pH
was adjusted to 1.6 with 5M HCl. 4 mL of the 0.5 wt% capsule suspension and 1 mL of a con-
centrated RGL dispersion were added (in the experiment without enzymes 1 mL Milli-Q water
was added) and a sample (t = 0) was withdrawn. The composition (without of enzyme) of the
resulting SGF medium is given in Table 1. The medium also contained pepsin (450 U mL-1)
and the activity of RGL was 100 U mL-1. The composition of the SGF and the enzyme concen-
trations are based on previous studies [17, 18]. The pH was maintained at pH 1.6 by adjusting
with 5M HCl. The gastric step was 1 hour or 3 hours long.
Small intestinal step. After one hour of gastric digestion (the 3 hours gastric step was not
continued), the composition of the medium was changed to mimic the fasted state simulated
intestinal fluid (SIF) by adding a concentrated SIF (pH ~ 6.3). The pH was adjusted with a 0.2
M NaOH solution to pH 6.5. A concentrated dispersion of pancreatic extract in Milli-Q water
(5 mL) was added to initiate the intestinal digestion (Pancreatic lipase activity 600 USP U mL-1
in the SIF medium) [19, 20]. In experiments without enzyme, Milli-Q water (5 mL) was added
instead. The pancreatic extract suspension was prepared as described previously [21]. The
composition of the SIF medium is given in Table 1 [22, 23]. During the lipolysis, the pH was
maintained at 6.5 by automatic addition of 0.2 M NaOH solution. The intestinal digestion step
was conducted for either 1.5 or 95 hours. In 95 hour experiments, in order to avoid massive
evaporation, the digesta was transferred (after 26.5 h) to a closed system and incubated at 37˚C
in a heating cabinet under slow magnetic stirring. The pH was not adjusted in the closed sys-
tem and dropped only slightly (pH ~ 6.4).
Enzyme cocktail step. The combined activities of the enzymes in the enzyme cocktail
(Pectinex Smash XXL, Novozyme 863, Viscozyme L and Pulpzyme HC) was chosen based on
previous experience and used to ensure the decomposition of RG-I. The enzymes cocktail was
Table 1. The composition of the SGF and SIF media (devoid of enzymes).
NaCl (mM) Phospholipid (mM) Bovine Bile Extract (mM) Tris (mM) Maleic acid (mM) CaCl22H2O (mM)
SGF (25 mL) 34.2 0.02 0.08 — — —
SIF (40 mL) 50 0.26 2.95 2 2 1.4
doi:10.1371/journal.pone.0168050.t001
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added to the SIF medium after 1.5 hours to obtain the following enzyme activities: Pectinex
Smash XXL (90 PECTU mL-1), Novozyme 863 (15 PGNU mL-1), Viscozyme L (0.5 FBG mL-1)
and Pulpzyme HC (4.6 AXU mL-1). The pH was maintained at 6.5 (automatic addition of 0.2
M NaOH). After 21.5 hour a sample was taken out and analyzed. As no additional release of
dye could be detected, extra enzyme was added to obtain the additional enzyme activities: Pec-
tinex Smash XXL (625 PECTU mL-1), Novozyme 863 (106 PGNU mL-1), Viscozyme L (3.4
FBG mL-1) and Pulpzyme HC (32 AXU mL-1). The suspension was transferred to a closed sys-
tem and the enzymatic digestion was continued in a heating cabinet at 37˚C under slow mag-
netic stirring for an additional 72 hours.
Samples (500 μL) were withdrawn during the different steps and lipase inhibitor was added
(2.5 μL of 1 mM BPBA in methanol) to the withdrawn sample when they contained pancrea-
tin. The samples were centrifuged at 4000 rpm for 5 min and the supernatant was collected
and diluted 10 times prior to fluorescence measurements. The release was calculated as the dif-
ference between the amounts of dye at time t subtracted by the amount of dye present at time
zero (t = 0). Volume changes (evaporation, dilution, sample withdrawal) were taken into
account in the calculations.
Characterization
Infrared spectroscopy. Infrared spectroscopy spectra were obtained using an ABB
MB3000 (ABB, Switzerland). Freeze-dried capsule samples (1–3 mg) were compounded with
ca. 110 mg KBr and pressed into pellets. All pellets were further dried prior to measurements.
Spectra from 400–4000 cm-1 were collected (32 scans, resolution of 1 cm-1).
Transmission electron microscopy. Transmission electron microscopy images of ultra-
thin sections of capsules were obtained using a Philips CM 100 TEM (Philips, the Nether-
lands). Capsules were first embedded in gelatin (10%), cut in small cubes, stained with OsO4
and dehydrated in graded series of ethanol and embedded in EPON. The size and wall-thick-
ness of capsules were analyzed using Image J (NIH, U.S.). The average diameter was calculated
from 200 measurements and the average capsule wall thickness was calculated from 50
measurements.
Fluorescence spectroscopic measurements. Emission spectra were recorded using an
excitation/emission wavelength of 587/605 nm with a Spex Fluorolog 3–22 (Jobin Yvon Hor-
iba, France) using an excitation and emission slit width of 2 and 5 nm, respectively. The
amount of dye released from the capsules was calculated from a calibration curve that was set
up using different concentrations of dye in water.
13C CP/MAS NMR measurements. 13C cross-polarization (CP) MAS NMR experiments
were carried out at room temperature on a Bruker Avance 400 spectrometer (Bruker Biospin,
Rheinstetten, Germany) operating at Larmor frequencies of 400.13 and 100.62 MHz for 1H
and 13C, respectively, using a double-resonance probe equipped for 4 mm (o.d.) rotors and a
spin-rate of 8000 Hz. Spectra were recorded using a recycle delay of 4 s, 4096 scans and a con-
tact time of 1 ms (rf-field strength of 80 kHz for both 1H and 13C) were utilized for the variable
amplitude CP/MAS experiments [24]. High-power TPPM [25] 1H decoupling (rf-field
strength: 80 kHz) was applied during an acquisition time of 40.9 ms. All spectra were refer-
enced (externally) to the carbonyl resonance of α-glycine at 176.5 ppm.
SEC-MALLS analysis. The size-exclusion chromatography (SEC) set-up used was the
SECcurity GPC System (PSS Polymer Standard Services GmbH, Mainz, Germany), which con-
sisted of the Agilent 1260 Infinity isocratic pump (G1310B Iso Pump), autosampler (G1329B
ALS), refractive index detector (G1362A RID), a multi-angle laser light scattering (MALLS)
detector (BIC-MwA7000, Brookhaven Instrument Corp., New York, USA), and a column set
RG-I Microcapsules for Targeted Drug Release
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including GRAM precolumn (10 μm, 8×50 mm), 100 Å (10 μm, 8×300 mm), and 10000 Å
(10 μm, 8×300 mm) analytical columns (PSS Polymer Standard Services GmbH, Mainz, Ger-
many). The columns were thermostated in the SECcurity column compartment at 60˚C and
the MALLS and RI detectors were thermostated at 45˚C. The RG-I sample was directly dis-
solved in the SEC eluent of dimethyl sulfoxide (DMSO, HPLC grade) with 0.5 wt% LiBr
(ReagentPlus) at 60˚C. The sample concentration was in the range of 0.4–2 g/L. The injection
volume was 100 μl and the flow rate was 0.5 mL/min. The differential refractive index incre-
ment (dn/dc) value for RG-I in DMSO/LiBr 0.5 wt% was measured on-line using the peak area
detected by the RI detector. The RI detector constant was determined by the injection of pullu-
lan standards of known molar masses and dn/dc value provided by PSS Polymer Standard Ser-
vices GmbH (Mainz, Germany). Data acquisition and processing were carried out by use of
WinGPC software (PSS Polymer Standard Services GmbH, Mainz, Germany).
Results and Discussion
Rhamnogalacutronan I
The overall architecture of the RG-I resembles that of a bottlebrush with a central backbone of
the repeating disaccharide [-4)-α-GalA-(1!2)- α-Rha-(1!-], see Fig 1A. The GalA residues
of the backbone are highly acetylated in many species, e.g potato, while the Rha residues carry
neutral sugar side-chains (the hairs of the bottle brush, hence the name “hairy regions” coined
by Schols et al [26]). The absolute molar mass of RG-I was analyzed by SEC with online
MALLS and RI detection. The dn/dc value for RG-I in DMSO/LiBr 0.5 wt% was 0.0605 mL/g,
as determined with the RI detector using a series of known concentrations of the RG-I sample
(S2 Fig, Supporting Information). The RG-I used in the present study had a weight average
molar mass (Mw) of 9.606 × 105 Da, a number average molar mass (Mn) of 6.005 × 105 Da, and
a polymer dispersity index (PDI) of 1.60. The molar mass distribution of RG-I is shown in Fig
1B. Approximately, 84% of the RG-I sample has a molar mass in the range from 4.0 × 105 Da
to 3.5 × 106 Da. And there is also a fragment (ca. 16%) of smaller RG-I molecules in the range
of 8.0 × 104–4.0 × 105 Da.
RG-I based Microcapsules
The RG-I based microcapsules were successfully synthesized using an inverse emulsification
technology. The inverse emulsion was formed by mixing (ultra-sonication) an aqueous phase,
containing RG-I and sodium chloride, with an oil phase consisting of cyclohexane and poly-
glycerol polyricinoleate, see the experimental section for details. The capsule wall was formed
via a cross-linking process involving the carbohydrate hydroxyls at the oil-water interphase of
the aqueous droplets using toluene diisocyanate (TDI) as the cross-linker. TEM micrographs
of cross-sections of the synthesized capsules revealed the capsule structure, see Fig 2A. The
average size of the capsules was 0.91 ± 0.62 μm and the thickness of the capsule wall was
14.4 ± 2.1 nm (when cross-linked with 1.4×10−3 mol TDI). The size distribution was quite
broad as shown in Fig 2B. The calculated capsule wall thickness was ~30 nm (calculated as
described previously [27] using ρurea/urethane = 1.25 g cm-3 and ρRG-I = 1.5 g cm-3 in the calcula-
tions), i.e. the measured capsule wall (14.4 ± 2.1 nm) is thinner than expected (~30 nm) based
on the amount of polymer used in the synthesis. This is probably due to that not all polymer
participated the capsule wall formation. As an indication of this, in the TEM cross-sections it
was possible to see darker areas at the outer capsule shell wall which is most likely diisocyanate
debris from capsule synthesis (arrow in Fig 2A). In addition some internal structure, probably
due to RG-I, was also visible inside the capsules (see Fig 2C).
RG-I Microcapsules for Targeted Drug Release
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The formed RG-I capsules contained polyurea/urethane cross-links as confirmed by FTIR
results presented in Fig 3A. The typical bands for RG-I (Fig 3A) were found at 3370 cm-1
(assigned to O-H stretching), 1740 cm-1 (stretching vibrations of C = O present in the RG-I
backbone) and 1620 cm-1 (stretching of C = O in the COO- deprotonated carboxylic functions)
[28]. The isocyanate groups of TDI reacted with the hydroxyl groups of RG-I molecules to
form urethane groups (−C = O of urethane at 1714 cm-1, shoulder in spectrum II). In addition,
the isocyanate groups of TDI were hydrolyzed by water to form amine groups and these fur-
ther reacted with other isocyanate groups and therefore urea bonds could also be found in the
capsule shell (−C = O of urea at 1653 cm-1) [29, 30]. By adding more TDI, the intensity of urea
peak increased further, as observed in the FTIR spectra (II) and (III) in Fig 3A, which was
rationalized by the enhanced reaction of the isocyanate groups with water resulting in urea
formation. Some un-reacted isocyanate groups were also present (2276 cm-1, spectra II and
III in Fig 3A). These reactive isocyanate groups can be used to functionalize the outer capsule
surface or be hydrolyzed to amine groups by transferring the capsules to water, as previously
Fig 2. Morphology of capsules. (a) TEM micrographs of the synthesized capsules showing the capsule structure. The arrow points
to a darker area, most likely diisocyanate debris from capsule synthesis. (b) Histogram showing the distribution in capsule size. (c) A
close-up of a synthesized capsule, showing the cell wall (marked) and the structure of the interior of the capsule.
doi:10.1371/journal.pone.0168050.g002
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demonstrated for TDI cross-linked starch nano-capsules [16]. The FTIR spectra for the surfac-
tant (PGPR) used in the capsule synthesis is given in the Supporting Information, S3 Fig.
The presence of both urethane and urea linkages in the capsule wall was further supported
by solid state 13C CP/MAS NMR, see Fig 3B. Previous 13C NMR studies report chemical shifts
of the carbonyl group in the urethane bond at 158 ppm (diisocyante grafted onto cellulose)
[31], at 155.6 ppm (aromatic diisocyante and glycidyl azide polymer) [32] and at 152.75 ppm
(polyurea formed by toluene diisocyanate reaction with water) [30]. Note that the latter is simi-
lar to the urea formation for the present capsules. The 13C CP/MAS NMR spectrum of the
capsule in Fig 3B, displays a broad resonance centered at 155 ppm, which is believed to be
Fig 3. FTIR and 13C CP/MAS NMR. (a) FTIR data for neat RG-I (I) and RG-I polyurea/urethane capsules prepared using different amounts
of TDI: 0.44×10−3 mol (II) and 1.3×10−3 mol of TDI (III). (b) 13C CP/MAS NMR spectra of pure RG-I and the RG-I polyurea/urethane capsule
prepared using 0.44×10−3 mol of TDI. The lower NMR spectrum is the difference between the spectrum of the capsule and pure RG-I.
doi:10.1371/journal.pone.0168050.g003
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overlapping resonances originating from carbonyl groups in both urea and urethane linkages
in the capsule wall.
The lower NMR spectrum in Fig 3B, is the difference between the spectrum of the capsule
and the spectrum of pure RG-I. It was observed that resonances with negative intensity or a
dispersive line shape are present around 60, 70 and 101 ppm. This shows that C6 in galactose
as well as carbons in the pyranose ring including the anomeric carbons of Gal, Rha or GalA
are involved in the linkages between RG-I and TDI.
Release in vitro
Potential targeted drug delivery properties of the capsules were investigated by studying the
release of an encapsulated fluorescent probe (sulforhodamine 101, SR101) serving as a model
drug. The encapsulation efficiency was 96.6 ± 2.2%, when using 1.4×10−3 mol TDI in the cap-
sule synthesis. The release studies were performed by subjecting the capsules to different
sequences of simulated media; see experimental section for details on media compositions.
The results of the release studies are presented in Fig 4.
During one hour of exposure to simulated fasted state gastric fluid (SGF, pH: 1.6, 450 U/
mL pepsin and 100 U/mL of gastric lipase) negligible release of SR101 from the capsules was
observed, see A in Fig 4. The same trend (no release) was observed when increasing the expo-
sure time to 3 hours of SGF, which indicates that the capsules should be stable enough to with-
stand the acidic conditions and enzymes present in the stomach. The residence time a meal or
a dosage form in the stomach of humans is dependent on the composition and caloric output
of the ingested bolus, but the average half-emptying time is approximately 60 min [18]. After
SGF exposure, some capsules were further exposed to simulated fasted state intestinal fluid
(SIF), which was achieved by adding a concentrated solution of amongst others, different salts
and surfactants (bile salt and phospholipids) to the SGF suspension containing capsules, and
adjusting the pH to 6.5 (see Table 1 for composition). To this medium, pancreatic extract was
added (600 U/mL) and the lipolysis was carried out for 1.5 hours at a constant pH. The result-
ing release was only minor (3.2%) (B in Fig 4) and increasing the exposure time to 95 hours
Fig 4. Release of dye from capsules. The release of SR101 (%) from microcapsules (1.4×10−3 mol TDI) exposed to simulated
media (see Table 1 and experimental section for compositions): A: simulated fasted state gastric fluid (SGF) for 1h or 3h. B: SGF (1h)
and simulated fasted state intestinal fluid (SIF, 1.5h). C: SGF (1h) SIF (95h). D: SGF(1h), SIF(1.5h) and Enzyme cocktail (93.5 h) E:
SGF without pepsin and gastric lipase (1h) and SIF without pancreatin (95h). The SGF (1h) and SIF (1.5h) experiments in B are the
same as those presented in D, but in the D the subsequent exposure to the enzyme cocktail (93.5h) is also included. Note that in all
cases (A-E), the release of dye in SGF step is very low. The results are an average of two (B, D) or three (A, C, E) release experiments.
doi:10.1371/journal.pone.0168050.g004
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resulted in a release of 4.5% (C in Fig 4). As a comparison, a combined SGF and SIF experi-
ment without pepsin, gastric lipase and pancreatic extract was also conducted (E in Fig 4),
with results similar to those in C, suggesting that the observed (low) release in C was due to
other mechanisms than enzymatic cleavage of the capsule wall by pepsin, pancreatic enzymes
or gastric lipase. These mechanisms are likely to include the presence of surface-active bile
salts, inducing release of SR101. More studies are however needed to fully elucidate this aspect.
The results in Fig 4 also suggest that the capsules are not degraded by gradual dissolution/ero-
sion mechanisms, as in the case with the pectin beads prepared by ionotropic gelation [1, 3].
One aim of the current paper was to prove that the RG-I capsules can be opened by
enzymes that could potentially be secreted by the colonic microbiota. However, the composi-
tion of the microbiota and derived enzymes in the colon is the focus of a growing number of
research initiatives, due to the strong correlation between health and the microflora [33]. Pres-
ently, the polysaccharide hydrolysis in the colon, and the involved microbial enzymes, is
poorly understood [34]. Therefore appropriate in vitro models for the colonic degradation of
RG-I do not exist. Thus, an enzyme cocktail (Pectinex Smash XXL, Novozyme 863, Viscozyme
L and Pulpzyme HC) was chosen based on previous experience, and the combined activities
were used to ensure the decomposition of the RG-I. The enzymes chosen will act on the side
chains as well as the backbone of RG-I. After 93.5 h of incubation, an additional 27% of the
SR101 was released (D in Fig 4). This is approximately 9 times more than what was released in
the preceding SGF and SIF steps; a total of 3.2% was release in the SGF and SIF step of D in Fig
4. Note that the SGF (1h) and SIF (1.5h) experiments in B are the same as those presented in
D. The large release in the presence of the enzyme cocktail, successfully demonstrates that the
capsule wall can be enzymatically cleaved despite the presence of polyurea/urethane linkages.
By altering the density of the polyurea/urethane network, the enzymatic degradation rate/the
release rate of the dye could also potentially be further tailored, as demonstrated previously for
lignin-based nano-container systems cross-linked by TDI [35].
Conclusions
The present study demonstrates that it is possible to synthesize aqueous-core microcapsules
utilizing the branched structure of the pectin macromolecule, Rhamnogalacturonan-I (RG-I),
in the capsule wall formation. The RG-I based capsules were filled with sulforhodamine 101
(dye) and tested for potential targeted delivery properties in the gastro intestinal tract. No
release from the microcapsules was observed upon exposure to simulated fasted state gastric
fluid and only a small amount was released during in vitro digestion under the simulated
fasted state intestinal conditions. However, upon exposure to a cocktail of four commercial
RG-I cleaving enzymes, potentially present in the colon, the capsules were opened. This sug-
gests that the RG-I based capsules have the potential to form an oral delivery platform with
colon-targeted drug delivery properties. However, to further confirm this, in vivo studies are
needed.
Supporting Information
S1 Fig. Fluorescence data for dye in different media. Normalized fluorescence of dye, sulfor-
hodamine 101, subjected to sequence of different simulated intestinal fluid, Gastric step: SGF
of pH: 1.6 with 450 U/mL pepsin and 100 U/mL of gastric lipase. Small Intestinal step: SIF
with pH: 6.5, pancreatin, 600 U/mL. Enzyme cocktail: pH 6.5, Pectinex Smash XXL (90
PECTU mL-1), Novozyme 863 (15 PGNU mL-1), Viscozyme L (0.5 FBG mL-1) and Pulpzyme
HC (4.6 AXU mL-1). The fluorescence intensities were normalized by dividing with the aver-
age fluorescence intensity obtained for the Gastric step at t = 0. All datapoints were an average
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of two measurements.
(PDF)
S2 Fig. RI peak area plotted vs. the injected mass for five different concentrations of
Rhamnogalacturonan-I. The dn/dc can be obtained from the slope, which depends on the RI
detector constant and the dn/dc.
(PDF)
S3 Fig. FTIR data including the surfactant PGPR.
(PDF)
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